CN105873583A - 用于降低慢性肾病患者的心力衰竭的枸橼酸铁 - Google Patents

用于降低慢性肾病患者的心力衰竭的枸橼酸铁 Download PDF

Info

Publication number
CN105873583A
CN105873583A CN201480072217.1A CN201480072217A CN105873583A CN 105873583 A CN105873583 A CN 105873583A CN 201480072217 A CN201480072217 A CN 201480072217A CN 105873583 A CN105873583 A CN 105873583A
Authority
CN
China
Prior art keywords
ferric citrate
iron
patient
ckd
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480072217.1A
Other languages
English (en)
Chinese (zh)
Inventor
恩里克·普拉多苏
罗恩·本图尔
詹姆斯·F·奥利维耶罗三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keryx Biopharmaceuticals Inc
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of CN105873583A publication Critical patent/CN105873583A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201480072217.1A 2013-11-04 2014-11-03 用于降低慢性肾病患者的心力衰竭的枸橼酸铁 Pending CN105873583A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
US61/899,866 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
CN105873583A true CN105873583A (zh) 2016-08-17

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480072217.1A Pending CN105873583A (zh) 2013-11-04 2014-11-03 用于降低慢性肾病患者的心力衰竭的枸橼酸铁

Country Status (15)

Country Link
US (3) US20160256486A1 (enExample)
EP (2) EP3747432A1 (enExample)
JP (3) JP2016535780A (enExample)
KR (1) KR102392441B1 (enExample)
CN (1) CN105873583A (enExample)
AU (1) AU2014341975A1 (enExample)
BR (1) BR112016009901A8 (enExample)
CA (1) CA2928200A1 (enExample)
EA (1) EA201690926A1 (enExample)
HK (1) HK1223031A1 (enExample)
IL (1) IL245317A0 (enExample)
MX (1) MX2016005734A (enExample)
SG (1) SG11201603091QA (enExample)
TW (2) TWI744215B (enExample)
WO (1) WO2015066593A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613662A (zh) * 2018-10-29 2021-11-05 法码科思莫斯控股有限公司 用羧基麦芽糖铁治疗铁缺乏

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140016438A (ko) 2009-07-21 2014-02-07 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
ES2834485T3 (es) 2013-06-05 2021-06-17 Tricida Inc Polímeros de unión a protones para administración oral
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
MA41150B1 (fr) 2014-12-10 2020-06-30 Tricida Inc Polymères de liaison aux protons pour administration orale
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
IL273960B2 (en) 2017-11-03 2025-08-01 Tricida Inc Nonabsorable compositions for use in treating or preventing metabolic acidosis
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
TW202313072A (zh) * 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374416A (zh) * 2006-01-30 2009-02-25 环亚有限公司 逆转、防止、延迟或稳定软组织钙化的方法
CN102573807A (zh) * 2009-07-21 2012-07-11 凯克斯生物制药公司 柠檬酸铁剂型
CN104884055A (zh) * 2012-06-21 2015-09-02 凯克斯生物制药公司 柠檬酸铁在治疗慢性肾脏疾病患者中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (enExample) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) * 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
EP2594551B1 (en) * 2005-08-18 2025-02-19 Panion & BF Biotech Inc. Uses of pharmaceutical-grade ferric organic compounds
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
JP5827326B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374416A (zh) * 2006-01-30 2009-02-25 环亚有限公司 逆转、防止、延迟或稳定软组织钙化的方法
CN101378658A (zh) * 2006-01-30 2009-03-04 环亚有限公司 治疗慢性肾病的方法
CN102573807A (zh) * 2009-07-21 2012-07-11 凯克斯生物制药公司 柠檬酸铁剂型
CN104884055A (zh) * 2012-06-21 2015-09-02 凯克斯生物制药公司 柠檬酸铁在治疗慢性肾脏疾病患者中的应用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613662A (zh) * 2018-10-29 2021-11-05 法码科思莫斯控股有限公司 用羧基麦芽糖铁治疗铁缺乏
US11806329B2 (en) 2018-10-29 2023-11-07 Pharmacosmos Holding A/S Treating iron deficiency with ferric carboxymaltose
US12295934B2 (en) 2018-10-29 2025-05-13 Pharmacosmos Holding A/S Treating iron deficiency with ferric carboxymaltose
US12303486B2 (en) 2018-10-29 2025-05-20 Pharmacosmos Holding A/S Treating iron deficiency with ferric carboxymaltose

Also Published As

Publication number Publication date
TW202203910A (zh) 2022-02-01
US20190307791A1 (en) 2019-10-10
MX2016005734A (es) 2016-11-08
JP2016535780A (ja) 2016-11-17
TWI744215B (zh) 2021-11-01
TW201609088A (zh) 2016-03-16
HK1223031A1 (zh) 2017-07-21
EP3065734A4 (en) 2017-05-17
BR112016009901A8 (pt) 2020-04-14
US20160256486A1 (en) 2016-09-08
JP2019206562A (ja) 2019-12-05
KR102392441B1 (ko) 2022-05-02
EA201690926A1 (ru) 2016-09-30
JP2021073230A (ja) 2021-05-13
JP6828100B2 (ja) 2021-02-10
SG11201603091QA (en) 2016-05-30
KR20160096597A (ko) 2016-08-16
CA2928200A1 (en) 2015-05-07
US20250360167A1 (en) 2025-11-27
WO2015066593A1 (en) 2015-05-07
IL245317A0 (en) 2016-06-30
EP3747432A1 (en) 2020-12-09
EP3065734A1 (en) 2016-09-14
AU2014341975A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
AU2018203205B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
JP6828100B2 (ja) 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
JP2021091686A (ja) 鉄欠乏性貧血の治療におけるクエン酸第二鉄の使用
US20190269645A1 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1210013B (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
NZ742524A (en) Use of ferric citrate in the treatment of chronic kidney disease patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160817

RJ01 Rejection of invention patent application after publication